Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
HMN-214 is an orally bioavailable prodrug form of HMN-176, an indirect inhibitor of polo-like kinase (PLK) activity that inhibits proliferation of a variety of cancer cells.1,2 HMN-214 decreases the expression of multidrug resistance gene 1 (MDR1) in AB-A.1 cells and in tumors isolated from mice bearing multidrug-resistant KB-A1 xenografts.2 HMN-214 (20 mg/kg per day) reduces tumor volume in PC3, WiDr, and A549 mouse xenograft models.1 It does not decrease nerve conduction velocity or compound action potential amplitude in rabbit sciatic nerves in vivo when administered at a concentration of 30 mg/kg per day.
WARNING This product is not for human or veterinary use.
1. In vivo antitumor activity of a novel sulfonamide, HMN-
2. HMN-